title: Prevention and management of trigeminal herpes zoster and postherpetic neuralgia.
abstract: Herpes zoster (HZ, also known as shingles) is caused by the reactivation of a dormant varicella zoster virus and can be a source of significant morbidity. Oral manifestations can include vesicular eruptions of the mucosa, osteonecrosis with tooth loss, and postherpetic neuralgia (PHN). This article discusses treatment for trigeminal nerve involvement with herpes zoster, as well as for the painful syndrome PHN.
authors.affiliation: Oral and Maxillofacial Surgery Residency, Tripler Army Medical Center, Tripler AMC, Hawaii, USA.
authors.forename: James J
authors.initials: JJ
authors.lastname: Closmann
authors.forename: C G
authors.initials: CG
authors.lastname: Fielding
authors.forename: M A
authors.initials: MA
authors.lastname: Pogrel
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D006562:Herpes Zoster / Q000150:complications / Q000517:prevention & control* / Q000628:therapy; D053061:Herpes Zoster Vaccine / Q000627:therapeutic use; D006801:Humans; D007571:Jaw Diseases / Q000517:prevention & control / Q000628:therapy / Q000821:virology; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000209:etiology / Q000628:therapy / Q000821:virology*; D051474:Neuralgia, Postherpetic / Q000517:prevention & control* / Q000628:therapy / Q000821:virology; D010020:Osteonecrosis / Q000517:prevention & control / Q000628:therapy / Q000821:virology*; D014277:Trigeminal Neuralgia / Q000517:prevention & control / Q000628:therapy / Q000821:virology*
chemical_list: D000998:Antiviral Agents; D053061:Herpes Zoster Vaccine